Dec. 3 at 2:27 PM
$BNGO
“We believe the increase in the CLFS for the Category 1 CPT code 81195 will make it easier to offer OGM-based LDTs for hematologic malignancies due to the potentially more favorable reimbursement from payers,” said Alka Chaubey, chief medical officer of Bionano. “We believe the newly established payment level, which is substantially higher than the original pricing, is appropriate for the additional data collection, interpretation and reporting needed when using OGM for blood cancers. We also believe that establishing Category I CPT codes can raise the awareness of the utility and support for OGM in the oncology and clinical genetic testing communities, not only in the United States, but around the world as well.”
https://ir.bionanogenomics.com/news-releases/news-release-details/final-2026-clinical-lab-fee-schedule-indicates-47-increase
